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Graphical Abstract 
 
TOC 
c-Met is a tyrosine kinase and an important therapeutic target for anticancer drugs. In present study, we 
systematically investigated the influence of a range of parameters on the correlation between 
experimental and calculated binding energies of type II c-Met inhibitors. Results from this study will form 
the basis for establishing an efficient computational docking approach for c-Met type II inhibitors design. 
Highlights 
• Testing a set of influences to the ranking ability of the docking program in MOE. 
• Structure-activity relationship study of c-Met type II inhibitors. 
• Establishing an efficient computational docking approach for c-Met type II inhibitors design. 
ABSTRACT： c-Met is a transmembrane receptor tyrosine kinase and an important therapeutic 
target for anticancer drugs. In the present study, we systematically investigated the influence of a 
range of parameters on the correlation between experimental and calculated binding free energies 
of type II c-Met inhibitors. We especially focused on evaluating the impact of different force fields, 
binding energy calculation methods, docking protocols, conformation sampling strategies, and 
conformations of the binding site captured in several crystallographic structures. Our results 
suggest that the force fields, the protein flexibility, and the selected conformation of the binding 
site substantially influence the correlation coefficient, while the sampling strategies and 
ensemble docking only mildly affect the prediction accuracy. Structure-activity relationship 
study suggests that the structural determinants to the high binding affinity of the type II 
inhibitors originate from its overall linear shape, hydrophobicity, and two conserved hydrogen 
bonds. Results from this study will form the basis for establishing an efficient computational 
docking approach for c-Met type II inhibitors design. 
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 1. Introduction 
c-Met is a transmembrane receptor tyrosine kinase containing an extracellular α-chain of 50 
kDa, which is disulfide linked to a membrane-spanning β-chain of 145 kDa [1]. Upon binding 
with its high-affinity natural ligand, i.e. HGF (hepatocyte growth factor), c-Met dimerizes and 
each monomer undergoes the transphosphorylation of Y1234 and Y1235 in the activation loop 
(A-loop) in the intracellular kinase domain. The phosphorylation subsequently allows the 
autophosphorylation of Y1349 and Y1356 in the substrate binding site at the C-terminus [2]. The 
hyperactivation of c-Met often facilitates the proliferation, differentiation, and antiapoptosis of 
normal cells by inducing the activation of JAK/STAT [3, 4], Ras/MAPK [5, 6] and PI3K/Akt 
pathways [7]. An aberrant c-Met activity could therefore result in tumorigenesis, invasive growth, 
and cancer metastasis. HGF and/or c-Met have been implicated in a wide variety of solid tumors 
such as liver, breast, pancreas, lung, kidney, bladder, ovary, brain, and prostate cancers [8, 9].  
Overexpression of c-Met and/or HGF is often associated with a metastatic phenotype and poor 
prognosis, while the activation of HGF/ c-Met signaling confers resistance to cancer therapies [9]. 
Therefore, c-Met is an important therapeutic target for the development of anticancer drugs. 
Tremendous efforts have been devoted to the development of small-molecule c-Met inhibitors, 
thus leading to the identification of structurally diverse c-Met inhibitors with different binding 
modes [9]. Several inhibitors have been approved by FDA, among which crizotinib (Fig. 1E), 
which was given fast track approval in 2011 to treat patients with late-stage non-small cell lung 
cancer (NSCLC), and cabozantinib (Fig. 1E), which was approved for patients with medullary 
thyroid carcinoma (MTC) in 2012 [10]. Several drug candidates targeting c-Met have progressed 
into clinical trials, including INCB28060 (Phase I), tivantinib (Phase I), MK2461(Phase II), 
foretinib (Phase II), BMS-777607 (Phase II), MGCD265 (Phase II), EMD 1214063 (Phase I) and 
golvatinib (Phase I) [10]. Because c-Met inhibitors have the potential to treat a wide range of 
cancers, substantial efforts are made worldwide to develop more efficient and specific inhibitors 
with fewer side effects and higher selectivity. 
The known c-Met inhibitors in general can be classified into three classes (type I, type II and 
others) by virtue of their binding modes. Type I inhibitors adopt a U-shaped conformation and 
bind to the ATP binding site when the kinase has a ‘DFG-in’ conformation (Fig. 1A and B), in 
which the conserved DFG motif of the activation loop being in an ‘in’ conformation [11,32]. 
Crizotinib belongs to type I inhibitors that binds in an U-shaped conformation (Fig. 1A). The 
interactions between the R-methylbenzyloxy unit and the c-Met A-loop conformation are key to 
the potency of crizotinib [11]. In contrast, type II inhibitors bind to the kinase when it has a 
‘DFG-out’ conformation, in which the conserved DFG motif of the activation loop being in an 
‘out’ conformation [11]. These inhibitors bind to c-Met in a more extended conformation than 
type I inhibitors, stretching from the ATP-binding site to a deep hydrophobic pocket, as 
illustrated in Fig. 1C and 1D [11]. In the cocrystal structure of c-Met and foretinib, this type II 
inhibitor is deeply buried in the c-Met allosteric pocket with the 4-fluorophenylamine motif 
forcing the F1223 of the DFG motif in an inactive position. The 4-phenoxyquinoline of foretinib 
forms hydrogen bonds with D1222 as well as pi-pi interaction with F1223, further stabilizing the 
inactive conformation [12].  
It has been reported that the mutation of c-Met Y1230 leads to resistance against type I 
inhibitors but not to type II inhibitors [11]. Type II inhibitors do not interact with the gatekeeper 
tyrosine residues as they bind beyond the entrance of the active sites of c-Met [13]. Type II 
inhibitors are therefore in general not affected mutations that disrupt the binding of type I 
inhibitors. However, the majority of currently available type II c-Met inhibitors are multi-
targeted inhibitors, which correlates with side effects observed during clinical trials [14]. 
Because of the high structural and sequential conservation of the binding sites among different 
kinase proteins, development of novel type II inhibitors with improved specificity remains a 
challenge but is also promising for overcoming mutations that defeat current antitumor drugs.  
Molecular docking is a fast and efficient computational approach for determining the binding 
modes of c-Met type II inhibitors, and ranking their binding affinities. Accurate determination of 
the binding modes of these inhibitors is the first step for rational design of c-Met type II 
inhibitors with improved specificity. However, the accuracy of docking is limited to its capacity 
for dealing with the flexibility of the proteins, forcefield quality as well as conformation 
sampling methods. 
The present study was undertaken to study the influences of different force fields, docking 
strategies (rigid and flexible docking), the conformation sampling methods, as well as the energy 
calculation methods to the docking accuracy for formulation an optimal computational docking 
method to predict the binding modes and affinities of c-Met type II inhibitors. And the structure-
activity relationships of the c-Met type II inhibitors to c-Met were systematically investigated 
based on the computationally determined binding modes. The large number of c-Met inhibitors 
with reported activities [9,15-31] as well as the six c-Met crystal structures (pdb code: 2WGJ, 
2WKM, 3ZXZ, 3ZZE, 3LQ8 and 3U6I) [11,12,14,32] in complex with some of these inhibitors 
gave rise to the possibility to test our methods.  
 
 
2. Methords 
2.1. Computational Docking 
Molecular docking was performed using MOE [33]. Compounds 1 to 378, listed in 
supplementary table 1, were sketched in ChemDraw and minimized in MOE. The six crystal 
structures of the c-Met in complex with inhibitors (pdb code: 2WGJ , 2WKM, 3ZXZ , 3ZZE, 
3LQ8 and 3U6I) were retrieved from the protein data bank (http://www.rcsb.org). The binding 
site was assumed to be identical to that of inhibitors of the same type in the crystal structure. 
Both the ligand and the protein were protonated at physiological pH prior to docking. Several 
docking protocols, force fields and sampling methods as well as c-Met crystal structures were 
systematically investigated to assess their influence on the accuracy of ranking inhibitor potency. 
2.2. Molecular dynamics simulations  
Molecular dynamics (MD) simulations were carried out on the c-Met in complex with 
foretinib using the Amber 12 [34] package. Foretinib was selected as its structure is similar to the 
compounds we choose, which are typical type II c-Met inhibitors. GAFF and FF12SB force field 
were employed for the ligands and the receptor, respectively. Prior to the MD simulations, the 
complex was solvated into an octahedral box of TIP3P water molecules and neutralized by 
replacing 4 water molecules by 4 Cl- ions. The system was minimized to remove unfavorable van 
der Waals interactions. The minimization consisted of two steps. First, only the water molecules 
and ions were minimized with 1000 steps of steepest descent minimization followed by 1000 
steps of conjugate gradient minimization. Second, the restraint on the solute was removed and 
the whole system was relaxed with 3000 steps of steepest descent minimization and 3000 steps 
of conjugate gradient minimization. The cutoff of the non-bonded interactions was set to 12 Å 
for the energy minimization process. After minimization, MD simulation was performed. First, 
the solute was restrained and the whole system was gradually heated from 10 to 300 K in 100 ps 
in the NVT ensemble. Then the system was equilibrated in the NPT ensemble where the 
temperature and pressure were kept at 300 K and 1 atm, respectively. Finally, in the production 
process, the whole system was unconstrained and a 50 ns molecular dynamics process was 
carried out. For all MD simulations the time step was set to 2 fs, the particle mesh Ewald (PME) 
method [35] was applied to account for long-range electrostatic interactions and the lengths of 
the bonds involving hydrogen atoms were fixed with the SHAKE algorithm [36].  
2.3. Binding energy calculations  
Binding free energy calculation and decomposition was performed using the MMGBSA script 
in AMBER 12 as previously described [37]. Briefly, ten frames were extracted from the last 30 
ns of the MD trajectory at regular time intervals. The binding energies calculated on the ten 
frames were averaged. 
3. Results and discussion  
3.1. Influences from the force fields  
The performance of nine force fields was evaluated on ranking their ability to correctly rank 
the binding affinities of cMet type II inhibitors. Scatter plots of the correlation between 
computed and experimental binding energies and for the nine force fields are shown in Fig. 2. 
Docking using Amber10:EHT or Amber12:EHT force field gave the best ranking of the binding 
affinities of these compounds, and produced a Pearson product-moment correlation coefficient 
(R) of 0.52, which is only slightly better than that given by the Amber99, CHARMM27, OPLS-
AA or PFROSST force fields. However, application of the MMFF94, MMFF94s or MMFF94x 
force fields only showed very week correlations, with R between 0.24 and 0.27. The MMFF94 
was designed for modeling organic molecules, especially those of pharmaceutical interest [38], 
whereas the Amber force fields ff12 and ff10 were developed primarily for large proteins and 
nucleic acids [39]. The better performance of Amber force fields might originate from its better 
accuracy at modeling the dynamics of proteins. The Amber10:EHT and Amber12:EHT are 
recently developped force fields that combine Amber10 or Amber12 with Extended Hückel 
Theory (EHT) bonded parameters. When the Amber10/12EHT is applied to the docking, the 
Amber non-bonded model is used for all atoms, and the Amber10/12 or EHT bonded parameters 
are used where appropriate. Therefore, it is not surprising that application of the Amber10:EHT 
or Amber12:EHT force field to the docking produced a comparable correlation coefficient. To 
the best of our knowledge, our study is the first to systematically evaluate the influences of 
different force fields to the performance of computational docking. 
3.2. Evaluation of the MM/GBSA rescoring  
A recent computational modeling study reported that the MM/GBSA method was better at 
ranking small ligand binding affinities compared to docking scores [40]. MM/GBSA is an end-
point method that combines molecular mechanics (MM), Generalized Born (GB) implicit 
solvation model and accessible surface area (SA) to estimate binding free energies [41]. This 
method performs well for ranking binding pose predictions based on its free-energy estimations 
[42]. In this study, MM/GBSA was used to re-score the binding affinities of the c-Met type II 
inhibitors in induced fit docking based on London dG score to further improve the correlation 
between the predicted binding affinities and the binding affinities derived from the experimental 
data. Scatter plots of the correlation between binding energies calculated using MM/GBSA 
method and binding energies derived from experimental data are given in Fig. 3. Rescoring the 
binding affinities using MM/GBSA did not improve the binding energy ranking performance of 
the induced fit docking in MOE. MM/GBSA is a sensitive method, and insufficiently 
conformational sampling and inaccuracies in the binding poses might explain this disappointing 
result. The performance of London dG score is comparable to that of the MM/GBSA method. 
3.3. Influence from docking methods and sampling strategies 
The influence of docking protocols and energy sampling methods on binding energy 
predictions was evaluated. Scatter plots of the correlation of the binding energies calculated 
using different docking protocols and energy sampling methods versus energies derived from 
experimental data are given in Fig. 4. The induced fit docking protocol gave the best correlations 
and was distinctly better than the rigid receptor docking and virtual screening. The rigid receptor 
docking and virtual screening methods failed to produce any significant correlation between the 
calculated binding energies and the experimentally derived values, with R values of about 0.1. In 
contrast, binding energies calculated using induced fit method mildly correlated with 
experimental data, with R values around 0.4–0.5. The induced fit method was slightly improved 
by averaging energies of ten binding modes instead of only using the minimum energy for 
ranking compounds. In the induced fit docking, side chains of the residues occupying the binding 
site are considered flexible, which is effectively modeled using a rotamer-based library. The 
binding energies predicted by the induced fit method are overall lower than those computed 
using the rigid receptor docking and virtual screening, indicating that the fit between the ligand 
and receptor was better. Our results are consistent with previous studies in which flexible 
receptor docking gave better prediction than rigid-receptor docking [43]. Additionally, we show 
that combining induced fit docking with an averaging energies on several top-ranked binding 
modes gives optimal predictions. Averaging energies over several binding poses improve the 
performance of the induced fit docking probably because several configurations help decrease 
the sampling bias.  
3.4. Ensemble based docking  
In induced-fit docking, only the flexibility of the side chains in the binding site was considered, 
and we will here investigate the influence of backbone conformations. To consider the flexibility 
of the backbone, ten frames of 50 ns MD simulations of c-Met bound to a type II inhibitor (pdb 
code: 3LQ8) [12] were extracted and used for ensemble docking. The correlation between the 
binding energies from docking using multiple frames and energies derived from experiments are 
shown in Fig. 5. Several methods were used to compute the energies from these docking: 
averaging the minimum energy of all dockings with a different frame, only recording the 
minimum energy resulting from docking with each of the ten frames, or averaging the top 5, 10 
or 20 ranking energies from all the docking poses with all the ten frames. Fig. 5 shows that the 
method to compute the energy only had a minor impact on the correlation with experiments, with 
the averaging the top 20 ranking energies of all binding poses showing a small improvement 
(R=0.61) (Fig. 5E) to using a single frame docking (R=0.52) (Fig. 4D). Incorporation of 
backbone flexibility as sampled by MD simulations can therefore improve the performance of 
induced-fit docking in MOE. Previous studies have found that protein conformation sampling 
from MD simulations can improve the performance of virtual screening, which is consistent with 
our results [44-48].  
3.5. Influences of the activation state of c-Met 
To assess the effect of the conformation adopted by the c-Met binding site when in different 
activation state, docking was performed using crystal structures of c-Met bound with types I or 
type II inhibitors, which bound to either the DFG-in (active) or DFG-out (inactive) states of c-
Met, respectively. In the previous section, we investigated the influence of small conformational 
changes, which could be explored using MD simulations, whereas we here focus on larger 
change of conformations associated with different states of the molecular target. As shown in Fig. 
6, the docking of type II inhibitors into crystal structures of c-Met bound to a type II inhibitor led 
to significantly better correlation with experimental binding energies than using conformation of 
the kinase bound to type I inhibitors. Predictions made with the DFG-in kinase conformation has 
nearly no correlation with experimentally-derived values, stressing that it is essential to use the 
appropriate activation state of the molecular target for docking. The structures of type I and type 
II inhibitors are noticeably different, with the former having a ‘U’ shape and the latter adopting a 
linear shape, and these difference of shapes correspond to the different steric landscapes 
displayed by the ATP binding pocket in the two DFG states. The c-Met structure in a DFG-out 
conformation, which is bound by type II inhibitors, has a narrow and deep ATP binding pocket, 
whereas the DFG-in conformation has a comparatively shallower binding site. Overall, results 
from this study showed that success of docking is highly dependent on selecting the appropriate 
protein activation state conformation.  
3.6. Binding modes of the c-Met type II inhibitors  
To give a better understanding of the structure-activity relationship of the investigated 
compounds, their binding modes to the c-Met are here analyzed. The binding modes of the c-Met 
type II inhibitors were determined by docking of these compounds to the binding site of the c-
Met with DFG-out conformation using Amber10:EHT forcefield and induce fit docking. As 
shown in Fig. 7 A, the linear type II inhibitors are deeply embedded into a narrow binding site, 
and several aromatic rings form extensive interactions with hydrophobic residues of the binding 
pocket (Fig. 7B), which are M1160, M1211, Y1159, I1084, A1108, L1157, F1223, F1200 and 
I1130. The protonated heterocyclic amine group of the inhibitors is located outside of the binding 
pocket (Fig. S1) where it is exposed to the solvent, suggesting its little contribution to the 
binding affinity. Interestingly, the models suggest that the inhibitors M1160 and D1222 establish 
two similar hydrogen bonds at the interface, which might explain their high affinity for c-Met 
(Fig. S1). The predicted binding modes of all the docked compounds are consistent with those 
displayed in the crystallographic structures (Fig. 7 C and D). The inhibitors bind in an extended 
conformation that stretches from the kinase linker to the C-helix, with the heterocyclic amine 
group positioned outside of the binding pocket and the aromatic ring located near the C-helix. As 
shown in Fig. 7C the predicted orientation of compound 378 is nearly the same to that 
determined using crystallography with the only difference at the fluorine substituted aromatic 
ring in the middle of the molecule. In contrast, the predicted conformation of the aromatic ring of 
compound 133 (magenta) and 242 (gray) near the C-helix is remarkably different from that 
determined using crystallography (blue) (PDB code: 2RFN) (Fig. 7D). These binding mode 
differences might originate from differences in the conformation of the C-helix region between 
crystal structures, as the binding mode of compounds 133 and 242 in their respective crystal 
structures cannot be reproduced by docking in the 3LQ8 crystal structure because the C-helix 
would produce steric hindrance. Thus, it is essential to select the proper crystal structure of c-Met 
for accurate determination of the binding mode of the ligands.   
4. Conclusion 
We have studied the binding affinities of a set of 378 c-Met type II inhibitors to c-Met through 
molecular docking in MOE. Influences of different force fields, binding energy calculation 
methods, docking protocols, averaging of energies on multiple poses, conformation of the 
binding site of the crystal structures to the correlation coefficient between experimental and 
calculated binding free energies were systematically investigated, establishing an optimum 
computational screening approach for small compounds. Our results demonstrate the following: 
(i) the London dG score in MOE is sensitive to the selected force fields and the 
Amber10/12:EHT force field is the best for ranking the binding affinities of the compounds; (ii) 
the performance of the dG score in MOE is comparable to the performance of MM/GBSA; (iii) 
consideration of the flexibility of the binding site substantially improves the performance of 
docking; (iv) conformation sampling strategies only slightly affect the ability of docking for 
ranking the binding affinities of the compounds, and the dG docking score in MOE is not 
sensitive to small uncertainties in c-Met/compounds complexes; (v) using multiple frames from 
MD lead to a small improvement of docking predictions in MOE; (vi) the activation state of the 
binding site is essential to the binding affinity prediction, and the selection of the appropriate 
crystal structure is essential for the success of docking. To conclude, we can get the best result 
when we calculate the energy using Amber forcefield, induced fit docking method, and average 
sampling protocol on multiple frames extracted from MD, and a realtively high R value of 0.61 
is reached. 
The induced fit docking in MOE and other docking software does not consider the flexibility 
of protein backbone, and docking into alternative conformations generated using MD simulation 
can be used to take into account small backbone fluctuations. However, larger change of 
conformations, such as that of the DFG motif or activation loop associated with kinase activation 
status, is really challenging to predict using MD simulations. Therefore, access to a crystal 
structure bounds to a ligand with similar structure to the compound library to be screened is 
suggested to be essential for the docking.  
Regarding the structure-activity relationship of the type II inhibitors studied here, their 
interactions with c-Met are characterized by extended interactions between hydrophobic groups 
and two conserved hydrogen bonds with residues in the long and narrow binding cleft. In 
summary, we have successfully tested a set of influences to the binding affinity ranking ability of 
the docking program in MOE, forming the basis for efficient computational ranking the binding 
affinities of c-Met type II inhibitors and determination of their binding modes. In future, it will 
be interesting to test the same set of influences on other kinase systems using different 
computational docking programs. 
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Fig. 1. Crystal structures of complexes between c-Met and some of its inhibitors. A) (pdb code: 2WKM) and B) (pdb code: 
3ZZE ) binding mode of type I inhibitors Pf-02341066 and Pf-04217903. C) (pdb code:3U6I) and D) (pdb code: 3LQ8) binding 
mode of type II c-Met inhibitors. E) structure of several c-Met type I inhibitors (Crizotinib, INCB28060, PHA-665752) and c-
Met type II inhibitors (Cabozantinib, Golvatinib). The DFG motif was shown in red color in D. 
 
 
 Fig. 2. Influences of the force fields to the correlation between the binding energies from docking (y-axis) and from experiment 
(x-axis). The binding energies of the compounds were calculated using different force fields: Amber12:EHT (A), Amber10:EHT 
(B), Amber99 (C), CHARMM27 (D), MMFF94 (E), MMFF94s (F), MMFF94x (G), OPLS-AA (H), and PFROSST (I). For each 
force field, 378 compounds were docked into the binding site of the crystal structure of c-Met (pdb code: 3LQ8) and averaged 
energy sampling method. The experimental binding energies were derived from several studies [9,15-31]. 
 
  
Fig. 3. Correlations between binding energies calculated using MM/GBSA method and binding energies derived from 
experimental data. A) Binding energies calculated using only the top ranked binding mode resulting from a docking in a crystal 
structure of c-Met (pdb code: 3LQ8); B) Binding energies calculated as the average binding energies between the top 10 binding 
modes resulting from docking in a crystal structure of c-Met (pdb code: 3LQ8); C) Binding energies of the best scored binding 
mode among 10 frames extracted from MD. 
 
 
Fig. 4. Influences of the docking protocols and energy sampling methods to the correlation between experimentally derived (x-
axis) and computationally calculated (y-axis) binding energies. A)–F), the binding energies were calculated using different 
docking protocols, including induced fit (A,D), rigid receptor (B,E), and virtual screening (C,F). The binding energies of the 
docked ligands were computed two strategies, either as the minimum energy (A-C) or as the average energy (D-F) from 10 
binding modes generated by docking. The 378 compounds were docked into the binding site of the crystal structure of c-Met (pdb 
code: 3LQ8) using the Amber10:EHT force field. 
 
Fig. 5. Correlation between the binding energies derived from experiment (x-axis) and binding energies calculated from multi-
frame based docking (y-axis). The 378 compounds were docked into ten conformations of the c-Met binding site extracted from a 
50 ns MD simulation. The binding energies were computed as A) the average of the minimum binding energies obtained in each 
of the ten conformations, or B) the minimum binding energy whatever the binding site conformation, or C) the average of the 5 
minimum energies whatever the binding site conformation; or D) the average of the 10 minimum energies whatever the binding 
site conformation, or E) the average of the 20 minimum energies whatever the binding site conformation, or F) the average 
energy for all the binding poses whatever the binding site conformation. The 10 frames were evenly extracted from the 50 ns MD 
simulation of the crystal structure of c-Met in complex with type II inhibitor (pdb code: 3LQ8).   
 
 Fig. 6. Influence of the activate state of c-Met to the correlation between binding energies calculated from docking (y-axis) and 
binding energies derived from experiment (x-axis). The conformation of c-Met in six crystal structures of complexes between c-
Met and either type I (panels A, B, C and D) or type II (panels E, and F) inhibitors were used for docking. The type I inhibitors 
bind to the activated, DFG-in state of the kinase, whereas the type II inhibitors bind to the inactivated, DFG-out state of the 
kinase. A) to F) correspond to pdb codes 2WGJ, 2WKM, 3ZXZ 3ZZE, 3LQ8 and 3U6I, respectively.  
  
Fig. 7．Predicted binding modes of type II inhibitors to c-Met. A) Orientation of type II inhibitors in the ATP binding pocket. 
The inhibitors are shown in line representations, and the cross section of the binding pocket is fogged. B) Residues of the binding 
pocket interacting with the type II inhibitors. Residues that form hydrogen bonds with the ligands are labeled. Dashed lines 
represent hydrogen bonds at the interface. C-D) comparison of the binding mode of the compound determined by X-ray 
crystallography (pdb code: 3LQ8 in orange and 2RFN in blue) and predicted using docking of compounds 378 (yellow), 133 
(gray) and 242 (magenta), respectively. 
 
 
